About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Drug to Treat Lung Infections in Cyctic Fibrosis Failed

by Julia Samuel on January 9, 2015 at 12:33 PM
Font : A-A+

Drug to Treat Lung Infections in Cyctic Fibrosis Failed

KaloBios Pharmaceuticals Inc failed in a mid-stage study and put a pause to the development of its drug for lung infections in cystic fibrosis patients.

KB001-A, was the drug developed to delay worsening respiratory tract symptoms and reduce the extent of intake of antibiotics in patients with cystic fibrosis.

Advertisement

Cystic fibrosis also known as mucoviscidosis, is an autosomal recessive genetic disorder that affects mostly the lungs but also the pancreas, liver, and intestine.

Frequent lung infections cause a serious symptom of difficulty in breathing. Other symptoms including sinus infections, poor growth, and infertility affect other parts of the body.
Advertisement

An estimated 30,000 children are affected with Cystic fibrosis and occurs in the rate of 1 in 3400 births.

KB001-A was developed to treat lung infections caused by a powerful superbug, Pseudomonas aeruginosa.

The drug also failed to improve lung function, which was the trial's secondary endpoint. Patients with cystic fibrosis are on antibiotics to reduce infection.

The data on the complete report of the drug's failure was not yet analysed by KaloBios.



Source: Medindia
Advertisement
Advertisement
Advertisement

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Drug to Treat Lung Infections in Cyctic Fibrosis Failed Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests